The COVIVAC vaccine is a product of cooperation between the Central Institute of Hygiene and Epidemiology, the Institute of Vaccines and Medical Biology (IVAC), Hanoi Medical University and international organisations, all of which began in May 2020.
IVAC has carried out a number of preclinical studies for the vaccine in India, the United States, and Vietnam, with the results of the experiments proving that the injection is both safe and meets the relevant criteria in order to progress to human trials.
The first phase involves plans to recruit 120 healthy volunteers divided into five separate groups, receiving three doses of 1mcg, 3mcg, 10 mcg, and 1 mcg with a supplementary dose for placebo use, respectively.
The vaccination will consist of two injections administered 28 days apart, with the first volunteer set to be vaccinated in February.
After compiling research results from its initial phase, providing the vaccine meets safety standards and shows signs of strong immunity, the second phase will be conducted with a larger sample size.
